APOL1 and Duchenne muscular dystrophy: Biomarkers that were initially decreased in GC-naïve DMD patients relative to control then increased following GC treatment included angiotensinogen (ANGT), beta-Ala-His dipeptidase (CNDP1), apolipoprotein L1 (ApoL1) and insulin-like growth factor-binding protein 5 (IGFB5).